Results 11 to 20 of about 5,633 (190)

Febuxostat: a new drug for an old disease. Do we really need it?

Italian Journal of Medicine, 2013
BACKGROUND Febuxostat is a non-purine selective inhibitor of xanthine oxidase whose therapeutic effect is decreasing the serum uric acid concentration.
Giovanni Gulli, Luigi de Filippis
doaj   +3 more sources

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2

Antioxidants, 2023
Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism that acts as a novel regulator of adipogenesis. In pathological states, xanthine oxidoreductase activity increases to produce excess reactive oxygen species (ROS).
Yoshiki Higa, Masahiro Hiasa, Hirofumi Tenshin, Emiko Nakaue, Mariko Tanaka, Sooha Kim, Motosumi Nakagawa, So Shimizu, Kotaro Tanimoto, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Masahiro Oura, Kimiko Sogabe, Tomoyo Hara, Ryohei Sumitani, Tomoko Maruhashi, Hiroki Yamagami, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka, Masahiro Abe   +21 more
doaj   +2 more sources

Febuxostat methanol solvate

Acta Crystallographica Section E, 2011
In the title compound {systematic name: [2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid (febuxostat) methanol monosolvate}, C16H16N2O3S·CH4O, the benzene and thiazole rings in the febuxostat molecule are twisted at 5.3 ...
Qi-Ying Jiang, Jing-Jing Qian, Jian-Ming Gu, Gu-Ping Tang, Xiu-Rong Hu   +4 more
doaj   +2 more sources

Evaluation of analgesic activity of allopurinol and febuxostat in experimental analgesic models in mice

Indian Journal of Pain, 2015
Background: Allopurinol and febuxostat are xanthine oxidase inhibitors which are used in the treatment of hyperuricemia and gout. Pain is one of the important symptoms in gout patients.
Promod D Shankpal, J H Hotwani, Kunal A Chitnis, Dnyanesh S Tadke, Vijay R Kokani   +4 more
doaj   +2 more sources

FEBUXOSTAT FOR TREATMENT OF CHRONIC HYPERURICEMIA IN GOUT PATIENTS

Медицинский совет, 2017
Febuxostat, a selective  inhibitor of isoforms xantinoxydoreductase, it is an alternative to a limited number of medications to reduce urates levels  applied in recent decades.
M. S. Petrova, V. I. Mazurov, O. V. Inamova   +2 more
doaj   +3 more sources

Efficacy and safety of febuxostat in elderly female patients

Clinical Interventions in Aging, 2014
Tomohiro Mizuno,1,2 Takahiro Hayashi,3 Sayo Hikosaka,1 Yuka Shimabukuro,1 Maho Murase,1 Kazuo Takahashi,2 Hiroki Hayashi,2 Yukio Yuzawa,2 Tadashi Nagamatsu,1 Shigeki Yamada3 1Department of Analytical Pharmacology, Graduate School of Pharmacy, Meijo ...
Mizuno T, Hayashi T, Hikosaka S, Shimabukuro Y, Murase M, Takahashi K, Hayashi H, Yuzawa Y, Nagamatsu T, Yamada S   +9 more
doaj   +1 more source

Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis [PDF]

The Korean Journal of Internal Medicine, 2020
Background/Aims The safety and efficacy of febuxostat in patients with stage 4–5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients.
Sang-Hyon Kim, So-Yeon Lee, Ji-Min Kim, Chang-Nam Son   +3 more
doaj   +1 more source

High-Throughput mRNA Sequencing Reveals Potential Therapeutic Targets of Febuxostat in Secondary Injury After Intracerebral Hemorrhage

Frontiers in Pharmacology, 2022
Febuxostat is a urate-lowering medication for the treatment of patients with gout. This study was performed to elucidate the effects and underlying mechanisms of febuxostat on neuronal injury induced by intracerebral hemorrhage (ICH) in mice. The results
Xueyan Wang, Chenyu Zhang, Chenyu Zhang, Yuwen Li, Yuwen Li, Ting Xu, Ting Xu, Jin Xiang, Yang Bai, Ying Zhang, Qi Wang, Tiejun Zhang, Linchuan Liao   +12 more
doaj   +1 more source

Impact of urate-lowering therapy on quality of life indicators in patients with gout

Современная ревматология, 2021
Gout can have a significant impact on the quality of life (QoL) of patients.Objective: to assess the dynamics of QoL indicators and the possibility of achieving the target level of uric acid (UA) in patients with gout on febuxostat therapy, with ...
M. N. Chikina, O. V. Zhelyabina, M. S. Eliseev   +2 more
doaj   +1 more source

The current treatment strategy for gouty arthritis

Современная ревматология, 2018
Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA).
M. S. Petrova, М. M. Musiychuk, V. I. Mazurov   +2 more
doaj   +1 more source